Background: We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER) database. Objective: We hypothesized that subjects with PIDD would have an increased incidence of cancer due to impaired immune function. Methods: Overall and site-specific cancer incidence rates were evaluated in subjects with PIDD (n 5 3658) enrolled in the USIDNET registry from 2003 to 2015 and compared with age-adjusted incidence rates in the SEER database. Results: We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with the age-adjusted SEER population (P < .001). Men with PIDD had a 1.91-fold excess relative risk of cancer compared with the age-adjusted male population (P < .001), while women with PIDD had similar overall cancer rates compared with the age-adjusted female population. Of the 4 most common malignancies in men and women in SEER (lung, colon, breast, and prostate cancers), we found no significant
recipients. 8 In these secondary immunodeficiencies, multiple factors can influence the risk of cancer including acquired or iatrogenic damage to the immune system or genotoxicity from pharmacotherapy. 9 Primary immunodeficiency diseases (PIDDs) are a group of >300 single gene defects affecting the immune system. 10 PIDD subjects provide the opportunity to dissect the role of immune protection at the level of specific genes and pathways, allowing us to test the concept of cancer immunosurveillance in subjects with compromised immune systems. An association of PIDD and cancers has been noted for many years 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and has been confirmed by single-center studies, 17 and from data collected in established registries. 12, [14] [15] [16] [18] [19] [20] The majority of studies were performed decades ago and involved small sample sizes with limited follow-up and no comparison groups. 12, [15] [16] [17] [18] [19] In an analysis of the Australasian PIDD data registry involving 1132 subjects, Vajdic et al 20 observed that only subjects with common variable immunodeficiency (CVID) and ataxia telangiectasia had an increased risk of cancer and that the spectrum of cancers was narrower than expected. The relative risk in relation to an age-matched general population was increased for non-Hodgkin lymphoma, leukemia, and gastric cancer. In this analysis, 78% of PIDD subjects had antibody deficiencies, while there was comparatively less representation of PIDDs that do not principally involve an antibody deficiency.
The purpose of our study was to evaluate the overall cancer incidence and site-specific cancer incidence in subjects with PIDD in the United States Immune Deficiency Network (USIDNET) database and compare those incidence rates with age-adjusted data from the general US population. The USIDNET is a research program of the Immune Deficiency Foundation formed in 2003 to provide support to investigate important questions in PIDD. One of the main tasks of the USIDNET has been the formation of a longitudinal registry of subject data, so that specific questions regarding the natural history and outcomes of these diseases can be collected over time. 11 To our knowledge, this is the largest population of PIDD subjects analyzed for incidence of cancers.
METHODS

USIDNET registry
The USIDNET registry collects a number of variables on subjects with PIDD including clinical, laboratory, and outcome data, which together provide a health survey of this rare group of subjects. The registry data are based on entries from physicians or their designees from 39 academic institutions in the United States who have institutional review board (IRB)-approved protocols and 5 medical offices that use the USIDNET IRB consent protocol. In addition, patients may enroll themselves, also using the USIDNET IRB consent; the data entered is abstracted from submitted released medical records. Physicians are encouraged to offer enrollment to all patients with a confirmed PIDD diagnosis and to not restrict enrollment to patients with a specific PIDD. We surveyed the registry to evaluate cancer incidence among PIDD subjects. Data were extracted using Boolean queries for specific data concerning the demographics and PIDD categories of all subjects with malignancy.
SEER estimated cancer incidence
The Surveillance, Epidemiology and End Results Program (SEER) of the National Cancer Institute is a coordinated system of population-based cancer registries that collects cancer incidence and survival data from 18 geographic areas throughout the United States that together represent approximately 26% of the US population and includes various diverse ethnic groups. 21 We used SEER data to create an age-adjusted cancer incidence for the general population in 5-year increments. We applied SEER incidence data and adjusted for age to estimate the expected incidence of cancer.
Statistical analysis
Demographics of the PIDD database were summarized with descriptive statistics. Statistical analysis was performed using frequency distributions. The chi-square test was used for categorical variables and the t-test was used for continuous variables. We generated age-adjusted cancer incidence using the SEER database and compared it with the incidence rates in the USIDNET registry using chi-square tests.
RESULTS
Cancer incidence in subjects with PIDD As of July 1, 2015, 3844 subjects with a PIDD diagnosis were included in the USIDNET registry. To be considered for analysis, subjects needed their PIDD diagnosis and age of last follow-up to The diagnosis categories represent the classification system published in Al-Herz et al. 10 AD, Autosomal dominant; AID, activation-induced cytidine deaminase; ALPS, autoimmune lymphoproliferative syndrome; APS-1, autoimmune polyendocrine syndrome type 1; AK2, adenylate kinase 2; APECED, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; BTK, bruton tyrosine kinase; CD, cluster of differentiation; CGD, chronic granulomatous disease; CHARGE, autosomal dominant genetic disorder caused by mutations in CHD7; DCLRE1C, DNA cross-link repair 1C; DOCK8, dedicator of cytokinesis 8; EDA-ID, anhidrotic ectodermal dysplasia with immunodeficiency; FAS, fas cell surface death receptor; FHL3, four and a half LIM domains 3; IKAROS, zinc finger protein; IL7R, interleukin 7 receptor; IPEX, immune dysregulation, polyendocrinopathy, X-linked; IRAK-4, interleukin-1 receptorassociated kinase 4; JAK3, janus kinase 3; MAC, macrophage antigen; NEMO, NF-kB essential modulator; PI3, phosphatidylinositol 3; PI3K, phosphatidylinositol 3 kinase; RAG, recombination activating gene; STAT, signal transducer and activator or transcription; TACI, TNF receptor superfamily; UNC13D, unc-13 homolog D; XIAP, X-linked inhibitor of apoptosis; XLP2, X-linked familial hemophagocytic lymphohistiocytosis; ZAP70, zeta chain of T-cell receptor-associated protein kinase 70.
be entered into the database by July 1, 2015. Because subjects in the database did not have the age of cancer diagnosis listed, age at last follow-up was used as a surrogate for age of cancer diagnosis. We excluded 186 subjects who did not have the age at last followup, which left 3658 subjects in the study. The mean age of subjects in the registry was 47 years, and Caucasian was the most common ethnicity (66.6%) (Table I) . 21, 22 CVID was the most common PIDD diagnosis, with 1285 entered subjects (35%) ( Table II) . 10 Subjects with other immune defects included 483 (13%) with chronic granulomatous disease, 430 (12%) with DiGeorge syndrome, 248 (7%) with severe combined immunodeficiency, 227 (7%) with Wiskott-Aldrich syndrome (WAS), 141 (4%) with Hyper IgM syndrome, and 844 (23%) with other diagnosis (Table II) . The registry consisted of 40.6% female versus 59.4% male subjects (the male predominance reflects the presence of X-linked PIDD). The range of age at last follow-up of our cohort was <1 year to 89 years of age.
There were 171 separate cancers reported in the cohort of 3658 PIDD subjects (4.7%). Ninety-one cancers were diagnosed in women and 80 cancers in men. Of the total cancers diagnosed, 82 (48%) were lymphoma, 25 (15%) were skin cancers, 14 (8%) were genitourinary, 14 (8%) were gastrointestinal cancers, 10 (6%) were breast cancers, 9 (5%) were endocrine cancers, 6 (4%) were cancers of the head and neck, 5 (3%) were lung cancers, 2 (1%) were bone cancers, and 4 (2%) were cancers with unspecified origins (Table III) .
Cancers were noted in only some of the PIDD categories (Table  IV) . As the most numerous of these, there were 119 cancers (70%) in subjects with CVID. Thirteen cancers (9%) were observed in subjects with hypogammaglobulinema and agammaglobulinemia and 8 cancers (4.6%) were observed in subjects with WAS. Despite the relatively high number of chronic granulomatous disease patients in the registry (483), none were diagnosed with cancer. The remaining cancers were diagnosed in subjects with various other PIDD diagnoses (Table IV) .
Comparison to age-adjusted cancer incidence Fig 1 summarizes the number of expected cancers versus actual cancers found in the PIDD subjects based on sex and their reported age at last follow-up. We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with the age-adjusted SEER population (P < .001) ( Table V) . Men with PIDD were diagnosed with any cancer at a 1.91-fold higher rate than the expected age-adjusted incidence of cancer in men based on SEER data (n 5 80 versus n 5 41.8; P < .001). In contrast, women in the USIDNET registry were diagnosed with cancer at a similar rate compared with the age-adjusted population (n 5 91 versus n 5 78.8; P 5 .169).
The most common cancer diagnoses in the SEER database were breast (women only), prostate (men only), lung, and colorectal cancers. We found no significant increase in the incidence of these cancers in subjects with PIDD versus the SEER database (Table V) . No male subject in the USIDNET registry was diagnosed with prostate cancer compared with the expected rate of cancer diagnosis in the age-adjusted population ENT, Ear-nose-throat; NOS, not otherwise specified. of 7.8 (P 5 .005). Ten female subjects in the USIDENT registry were diagnosed with breast cancer compared with the expected rate of breast cancer diagnosis of 24.6 (P 5 .003). There was no significant difference in the rates of lung cancer and colon cancer among PIDD patients versus the age-adjusted population. Cancers with the highest incidence rates among subjects in the registry were lymphoma, skin cancer, and leukemia. There was a significantly higher incidence of lymphoma (n 5 32 men and n 5 31 women in the registry) compared with the expected lymphoma incidence of 3.2 in men (P < .001) and 3.7 in women (P < .001) in the general population (Table V) . There was also a significantly higher incidence of skin cancer (10 men and 15 women in the USIDNET registry) versus the expected rate of skin cancer of 2.2 in men (P < .001) and 4.5 in women (P < .001). A limitation in comparing skin cancer rates is that in the USIDNET database, skin cancer was a global category, while in the SEER database, melanoma was the only skin cancer that has reportable population-based data on incidence and death. There was a similar incidence of leukemia in subjects in the registry versus the age-adjusted population. The rate of stomach cancer in the USIDNET subjects was similar to the age-adjusted population for men (n 5 2 in the USIDNET registry vs n 5 0.6; P 5 .075), and slightly increased in women (n 5 3 in the USIDNET registry vs n 5 0.8; P 5 .014). Finally, an increase in thyroid cancer occurred in men (4.44-fold increase; P 5 .001) but not in women with PIDD compared with the respective age-matched population.
Cancer incidence in CVID
While patients with CVID constituted 35% of the total number of PIDD patients in the registry, 70% of the cancer diagnoses occurred in CVID patients. Of the 1285 subjects with CVID, 119 (9.3%) were diagnosed with a cancer (Table VI) . Men in the CVID subgroup were diagnosed with a significantly higher rate of cancer than the age-adjusted male population (n 5 48 vs n 5 27.5; P < .001), while women with CVID were diagnosed with cancer at a similar rate as the age-adjusted female population (n 5 71 vs n 5 64.3, P 5 NS). Thirty-seven lymphomas were diagnosed in subjects with CVID, making this the most common cancer diagnosis. Skin cancer (n 5 23 cases) and breast cancer (n 5 8 cases) were the next most common cancer diagnoses in the CVID population.
Of the 4 most common malignancies in men and women in SEER (lung, colon, breast, and prostate cancers), there was no significant increase of these cancers in CVID patients versus the age-adjusted population. No patient with CVID had a diagnosis of prostate cancer compared with the expected rate of prostate cancer diagnosis of n 5 6.3 (P 5 .012). Eight women with CVID had a diagnosis of breast cancer versus the expected incidence rate of 21 (P 5 .004). Similar rates of lung and colon cancer were observed in both men and women with CVID versus the expected age-adjusted rates.
The cancers with the highest incidence rates in the subjects with CVID were lymphoma and skin cancer (Table VI) . There was a significantly higher incidence of lymphoma (n 5 16 in men and n 5 21 in women with CVID) compared with the expected lymphoma incidence of 1.9 in men (P < .001) and 3 in women (P <.001). There was also a significantly higher incidence of skin cancer (n 5 9 men and n 5 14 women with CVID) versus the expected rate of skin cancer (n 5 1.6 men and n 5 3.8 women) in the SEER database (P < .001). Gastric cancer was also more common than expected in the subjects with CVID (n 5 2 in men and n 5 3 in women with CVID vs expected rates of n 5 0.4 in men [P 5 .011] and n 5 0.7 in women [P 5 .005]). The incidence of thyroid cancer was higher in men (6.67-fold; P < .001) but not in women with CVID compared with the age-matched population. Cancer incidence in both men and women in the USIDNET registry as well as age-adjusted cancer incidence obtained from the SEER database in men and women. We used SEER data to create an age-adjusted cancer incidence for the general population in 5-year increments. We applied SEER incidence data and adjusted for age to estimate the expected incidence of cancer.
DISCUSSION
The USIDNET registry is supported by the National Institutes of Health to enhance the understanding and care of subjects with PIDD. For many years, attempts have been made to evaluate the excess number of malignancy in these subjects. As the USIDNET registry is populated with data on these rare diseases, we undertook an examination of the current registry to gain an up-to-date survey of cancers in PIDD. We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with the age-adjusted population (P <.001). The greatest increase in cancer incidence in PIDD was observed in lymphoma both in men (10-fold excess relative risk; P <.001) and women (8-fold excess relative risk; P < .001). This excessive lymphoma risk was largely driven by subjects with CVID, the most common PIDD in the registry. In male subjects with PIDD, an increase in skin cancer and thyroid cancer was observed relative to age-matched male subjects in the SEER database, while in female subjects with PIDD, an increase in skin cancer and stomach cancer was observed. Of the most common cancers in the general population (lung, colon, prostate, and breast), no increased incidence was observed in PIDD subjects. These data point to a restricted role of the immune system in protecting from specific cancers.
Non-Hodgkin lymphoma is the predominant malignancy in a number of PIDD, including CVID, ataxia telangiectasia, WAS, and severe combined immunodeficiency. 16 Since 70% of subjects in the PIDD registry with a cancer diagnosis had CVID, we performed a subgroup analysis of these subjects. Consistent with other studies, 14, 18, [23] [24] [25] [26] we observed an increased risk of nonHodgkin lymphoma, gastric cancer, and skin cancer in CVID subjects. In a study of 473 patients with CVID followed over 40 years, lymphoma was diagnosed in 8.2% and other cancers in 7.0% of patients; lymphoma was among the causes for increased mortality in CVID compared with age-and sex-matched population control subjects. 27 In an analysis of the Australasian Society of Clinical Immunology and Allergy PIDD registry of 1132 subjects from 79 centers in Australia, Vajdic et al 20 reported that only subjects with CVID and ataxia telangiectasia had an increased risk of cancer. A 1.6-fold excess relative risk of cancer was observed for all PIDD combined, and the relative risk in relation to an agematched general population increased for non-Hodgkin lymphoma, leukemia, and gastric cancer. 20 The increased incidence of gastric cancer in CVID has been attributed to increased achlorhydria 28 and to Helicobacter pylori infection. 29 However, more recently gastric cancer appears rarer in CVID, possibly due to the more common use of antibiotics that would eliminate H pylori.
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Data from national surveys suggest a US population prevalence of PIDD of 1 in 1200 persons. 30 National surveys of patients with 31 The 2007 survey included 13 possible PIDD diagnoses while the USIDNET registry includes a much broader range of PIDD. Also our cohort reflects a predominantly Caucasian population and minorities such as African Americans, Asians, and Hispanics are underrepresented; this observation may reflect underdiagnoses of PIDD among these minorities. 32 PIDD caused by defects in DNA repair are generally associated with other features, such as increased cellular sensitivity to radiation, developmental disorders, and cancers. Ataxia telangiectasia, Fanconi anemia, Bloom syndrome, and Nijmegen breakage syndrome have DNA repair defects associated with increased radiation sensitivity. 33 The cancer risk varies among these PIDDs, but, in general, they are at increased risk for lymphoma, leukemia, and other cancers 33 because of accumulated DNA damage. In CVID, the increased risk for lymphoma is likely multifactorial, including impaired control of EBV-driven lymphoproliferation and genetic instability of lymphocytes due to sustained activation and proliferation during chronic infections. [34] [35] [36] Even with a database as large as USIDNET, some rare PIDD were insufficiently represented or not included. For example, only 3 patients in the registry had GATA2 deficiency, a disorder characterized by immunodeficiency (monocytopenia, B cell, natural killer cell, and CD4 1 T-cell lymphopenia), neurologic manifestations, pulmonary disease, and susceptibility to myelodysplastic syndrome, acute myeloid leukemia, and solid tumor malignancies principally related to human papilloma virus (HPV)-associated dysplasias and squamous cell cancers. 37 The major strengths of the USIDNET database are its large size, data collection from multiple institutions, prospective reporting, and the broad range of represented PIDD. This study was the largest of its kind to evaluate tumor site-specific cancer incidence in subjects with PIDD and compare those incidences to age-adjusted populations from the SEER database. While registry databases allow collection of rare diseases, there are limitations in that reporting of cases is voluntary, and the diagnoses reported were not independently verified. In addition, the bias of missing data and underreporting in registries can be substantial. As an example, in the PIDD registry, there were no men with the diagnosis of prostate cancer and significantly fewer women with breast and colon cancer than the expected incidence. This unexpected finding is likely the result of underreporting of malignancies within the registry. However, if underreporting applied to the entire analysis, the finding of an increased incidence of lymphoma, skin, and gastric cancers may be larger than reported. In addition, the lack of a detailed description of cancer types in the USIDNET database may have led to incorrect classification of cancers and incorrect comparison with ageadjusted populations from the SEER database. When the age of diagnosis of cancer was not included in the registry, we used age at last follow-up as a surrogate for the year of cancer diagnosis, which can falsely increase the age of cancer diagnosis. Finally, our analysis was restricted to incident cancer and was not designed to address the separate question regarding how immunodeficiencies affect cancer prognosis. Epidemiologic studies in subjects with various immunodeficiencies point to a restricted role of our immune system in protecting against tumors. For example, AIDS-associated malignancies such as Kaposi sarcoma (caused by human herpesvirus-8), lymphomas (induced by EBV), and cervical and anal cancers (caused by HPV) largely represent defective viral immunosurveillance that predisposes to these cancers. The current study, as well as data from earlier registries, point to 2 major factors driving increased cancer risk among specific subjects with PIDD: defective DNA repair and failure to provide immune surveillance against chronic viral infections (eg, EBV and HPV) that cause cancer. However, we did not observe an increased incidence in PIDD patients of the most common solid tumor malignancies seen in the general population (lung, breast, colon, and prostate), an observation that supports a restricted role for immunosurveillance in preventing specific cancers while being less important for others.
